CytoSorbents Corp (CTSO)
Industry Medical Devices
This stock can be held in an Investment ISA and an Investment Account
Sell
$0.82
Buy
$0.90
$0.001 (+0.11%)
CytoSorbents Corp is a immunotherapy company. The Company uses blood purification to modulate inflammation with the goal of preventing or treating multiple organ failure in life-threatening illnesses and cardiac surgery.
Prices updated at 09 May 2025, 21:46 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
| Year | Gross margin (%) | Operating margin (%) | Net margin (%) | EBITDA margin (%) | EBITDA |
|---|---|---|---|---|---|
| 2024 | 70.59 | -47.16 | -58.21 | -54.13 | -19m |
| 2023 | 70.62 | -102.78 | -94.09 | -89.69 | -28m |
| 2022 | 52.47 | -107.36 | -111.76 | -103.51 | -30m |
| 2021 | 72.46 | -56.71 | -61.23 | -53.89 | -22m |
| 2020 | 71.99 | -26.29 | -19.86 | -24.61 | -10m |
| 2019 | 67.65 | -83.34 | -84.63 | -82.33 | -19m |
| 2018 | 63.02 | -76.95 | -84.98 | -78.90 | -16m |
| 2017 | 58.76 | -73.55 | -65.73 | -61.05 | -8m |
| 2016 | 51.82 | -140.04 | -143.35 | -142.44 | -12m |
Valuation data table
| Year | Price / Sales | Price earnings | Price / Cash flow |
|---|---|---|---|
| 2025 | 1.33 | - | - |
| 2024 | 1.47 | - | - |
| 2023 | 1.57 | - | - |
| 2022 | 2.15 | - | - |
| 2021 | 4.33 | - | - |
| 2020 | 8.34 | - | - |
| 2019 | 5.71 | - | - |
| 2018 | 12.70 | - | - |
| 2017 | 14.89 | - | - |
| 2016 | 19.48 | - | - |
| 2015 | 39.25 | - | - |
Price/Forward earnings (YTD)
-3.63
Returns
Debt profile
Returns data table
| Year | Return on assets (%) | Return on equity (%) | Return on invested capital (%) |
|---|---|---|---|
| 2024 | -41.30 | -119.80 | -48.69 |
| 2023 | -50.34 | -99.38 | -60.98 |
| 2022 | -42.96 | -67.00 | -50.47 |
| 2021 | -27.37 | -34.64 | -31.36 |
| 2020 | -13.36 | -18.97 | -15.71 |
| 2019 | -62.57 | -189.32 | -76.41 |
| 2018 | -59.04 | -126.56 | -65.03 |
| 2017 | -52.05 | -151.66 | -61.14 |
| 2016 | -112.31 | -246.41 | -119.12 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 4.27 |
| 2023 | 2.26 |
| 2022 | 1.79 |
| 2021 | 1.43 |
| 2020 | 1.14 |
| 2019 | 8.01 |
| 2018 | 2.02 |
| 2017 | 2.35 |
| 2016 | 7.25 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
